{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:11:36Z","timestamp":1788541896926,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/P027989\/1"],"award-info":[{"award-number":["MR\/P027989\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/21171-6"],"award-info":[{"award-number":["2016\/21171-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005639","name":"Universidade de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005639","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Tropica"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.actatropica.2020.105806","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T12:37:33Z","timestamp":1609245453000},"page":"105806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-2009","authenticated-orcid":false,"given":"Elizabeth M.","family":"Coser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9271-8049","authenticated-orcid":false,"given":"Bianca A.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edite H.","family":"Yamashiro-Kanashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Angelo L.","family":"Lindoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano C.","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actatropica.2020.105806_bib0001","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.actatropica.2020.105806_bib0002","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4269\/ajtmh.2001.65.466","article-title":"Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala","volume":"65","author":"Arana","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.actatropica.2020.105806_bib0003","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","article-title":"Topical paromomycin with or without gentamicin for cutaneous leishmaniasis","volume":"368","author":"Ben Salah","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.actatropica.2020.105806_bib0004","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.actatropica.2020.105806_bib0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1051\/parasite\/2019030","article-title":"First report of Leishmania (Viannia) lindenbergi causing tegumentary leishmaniasis in the Brazilian western Amazon region","volume":"26","author":"Cantanhede","year":"2019","journal-title":"Parasite"},{"key":"10.1016\/j.actatropica.2020.105806_bib0006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.actatropica.2020.105806_bib0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijpddr.2020.08.001","article-title":"Activity of paromomycin against Leishmania amazonensis: direct correlation between susceptibility in vitro and the treatment outcome in vivo","volume":"14","author":"Coser","year":"2020","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.actatropica.2020.105806_bib0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/00034983.1995.11812924","article-title":"Discrimination of Leishmania isolates using a limited set of enzymatic loci","volume":"89","author":"Cupolillo","year":"1995","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.actatropica.2020.105806_bib0009","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.trstmh.2008.09.008","article-title":"Paromomycin","volume":"103","author":"Davidson","year":"2009","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.actatropica.2020.105806_bib0010","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/jac\/dkt318","article-title":"In vitro interaction between paromomycin sulphate and four drugs with leishmanicidal activity against three New World Leishmania species","volume":"69","author":"de Morais-Teixeira","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.actatropica.2020.105806_bib0011","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4269\/ajtmh.16-0811","article-title":"Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis","volume":"96","author":"Espada","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.actatropica.2020.105806_bib0012","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1590\/0074-02760150128","article-title":"Leishmania (Viannia) naiffi: rare enough to be neglected?","volume":"110","author":"Fagundes-Silva","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.actatropica.2020.105806_bib0013","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.actatropica.2004.10.007","article-title":"Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis andLeishmania (Viannia) braziliensis","volume":"93","author":"Goncalves","year":"2005","journal-title":"Acta Trop"},{"key":"10.1016\/j.actatropica.2020.105806_bib0014","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4269\/ajtmh.17-0760","article-title":"Case Report: Atypical Cutaneous Leishmaniasis in a Patient with Mixed Leishmania guyanensis andLeishmania amazonensis Infection","volume":"99","author":"Gosch","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.actatropica.2020.105806_bib0015","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0035-9203(91)90226-O","article-title":"Human urine stimulates growth of Leishmania in vitro","volume":"85","author":"Howard","year":"1991","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.actatropica.2020.105806_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004118","article-title":"Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh","volume":"9","author":"Jamil","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.actatropica.2020.105806_bib0017","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.316.7139.1200","article-title":"Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar","volume":"316","author":"Jha","year":"1998","journal-title":"India. Bmj"},{"key":"10.1016\/j.actatropica.2020.105806_bib0018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molbiopara.2008.12.007","article-title":"Paromomycin: uptake and resistance in Leishmania donovani","volume":"164","author":"Jhingran","year":"2009","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.actatropica.2020.105806_bib0019","first-page":"1084","article-title":"Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression","volume":"10","author":"Kapler","year":"1990","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.actatropica.2020.105806_bib0020","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1371\/journal.pntd.0000381","article-title":"Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials","volume":"3","author":"Kim","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.actatropica.2020.105806_bib0021","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1128\/AAC.00812-10","article-title":"Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine","volume":"55","author":"Kulshrestha","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.actatropica.2020.105806_bib0022","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/tmi.13119","article-title":"Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial","volume":"23","author":"Machado","year":"2018","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.actatropica.2020.105806_bib0023","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.actatropica.2007.06.001","article-title":"Infectivity of five different types of macrophages by Leishmania infantum","volume":"103","author":"Maia","year":"2007","journal-title":"Acta Trop"},{"key":"10.1016\/j.actatropica.2020.105806_bib0024","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4269\/ajtmh.2012.12-0022","article-title":"In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis\u2013status of newly introduced drugs","volume":"87","author":"Prajapati","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.actatropica.2020.105806_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005635","article-title":"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh","volume":"11","author":"Rahman","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.actatropica.2020.105806_bib0026","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijpddr.2018.04.002","article-title":"Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs","volume":"8","author":"Rastrojo","year":"2018","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.actatropica.2020.105806_bib0027","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.actatropica.2020.105806_bib0028","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/jac\/dkp500","article-title":"In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent","volume":"65","author":"Seifert","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.actatropica.2020.105806_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/trstmh\/trz037","article-title":"What makes mucosal and anergic diffuse cutaneous leishmaniases so clinically and immunopathogically different? A review in Brazil","author":"Silveira","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.actatropica.2020.105806_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007253","article-title":"Topical paromomycin for New World cutaneous leishmaniasis","volume":"13","author":"Sosa","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.actatropica.2020.105806_bib0031","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.actatropica.2020.105806_bib0032","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for Visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.actatropica.2020.105806_bib0033","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1517\/14656566.6.16.2821","article-title":"Treatment of visceral leishmaniasis","volume":"6","author":"Sundar","year":"2005","journal-title":"Expert opinion on pharmacotherapy"},{"key":"10.1016\/j.actatropica.2020.105806_bib0034","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.actatropica.2020.105806_bib0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.actatropica.2020.105806_bib0036","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0035-9203(94)90106-6","article-title":"Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica","volume":"88","author":"Teklemariam","year":"1994","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.actatropica.2020.105806_bib0037","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1017\/S0031182016002523","article-title":"Chemotherapy of leishmaniasis: present challenges","volume":"145","author":"Uliana","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.actatropica.2020.105806_bib0038","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.exppara.2013.01.022","article-title":"Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model","volume":"134","author":"Utaile","year":"2013","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.actatropica.2020.105806_bib0039","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1128\/CMR.00104-14","article-title":"Species typing in dermal leishmaniasis","volume":"28","author":"Van der Auwera","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.actatropica.2020.105806_bib0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis","volume":"10","author":"van Griensven","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.actatropica.2020.105806_bib0041","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eclinm.2018.12.009","article-title":"Cutaneous Leishmaniasis Due to Leishmania aethiopica","volume":"6","author":"van Henten","year":"2018","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.actatropica.2020.105806_bib0042","first-page":"61","article-title":"Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis","author":"Wijnant","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.actatropica.2020.105806_bib0043","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1086\/507710","article-title":"American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?","volume":"194","author":"Yardley","year":"2006","journal-title":"The Journal of infectious diseases"},{"key":"10.1016\/j.actatropica.2020.105806_bib0044","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/IAI.71.3.1225-1233.2003","article-title":"Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages","volume":"71","author":"Zamboni","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.actatropica.2020.105806_bib0045","first-page":"68","article-title":"In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B","volume":"15","author":"Zauli-Nascimento","year":"2010","journal-title":"Trop Med Int Health"}],"container-title":["Acta Tropica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X20317198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X20317198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:26:43Z","timestamp":1757550403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001706X20317198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":45,"alternative-id":["S0001706X20317198"],"URL":"https:\/\/doi.org\/10.1016\/j.actatropica.2020.105806","relation":{},"ISSN":["0001-706X"],"issn-type":[{"value":"0001-706X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil","name":"articletitle","label":"Article Title"},{"value":"Acta Tropica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actatropica.2020.105806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105806"}}